RxDoctor Payments Data

Trenis Nash, NP

Family · Jackson, TNNPI 1598305336

Payments from drug & device makers

$4,996in general payments, 2019–2025

Across 256 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$758
  • Novartis$590
  • Boston Scientific$493
  • AstraZeneca$386
  • Amgen$365
  • Abiomed$364
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$4,94699%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,996 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$37,397
Medicare patients
270
Services billed
516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$145,845
EntrestoSacubitril/Valsartan41$41,728
JardianceEmpagliflozin18$23,287
XareltoRivaroxaban25$22,402
FarxigaDapagliflozin Propanediol35$19,482
BrilintaTicagrelor32$19,140
Ranolazine ErRanolazine22$3,382
Diltiazem 12hr ErDiltiazem Hcl11$2,657
Atorvastatin Calcium188$2,103
Diltiazem 24hr Er (Cd)Diltiazem Hcl42$1,554
Metoprolol Succinate190$1,521
Furosemide340$1,478
Losartan Potassium179$1,470
ClopidogrelClopidogrel Bisulfate121$1,374
Rosuvastatin Calcium80$1,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$153$145,845194 claims
NovartisEntresto$590$41,72841 claims
AstraZenecaFarxiga, Brilinta$386$38,62267 claims
Boehringer IngelheimJardiance$246$23,28718 claims
Johnson & JohnsonXarelto$267$22,40225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.

Other family in Jackson

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →